Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents

@article{Tamargo2014DiureticsIT,
  title={Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents},
  author={Juan Tamargo and J Segura and Luis M. Ruilope},
  journal={Expert Opinion on Pharmacotherapy},
  year={2014},
  volume={15},
  pages={605 - 621}
}
Introduction: Diuretics enhance the renal excretion of Na+ and water due to a direct action at different tubular sites of the nephron where solute re-absorption occurs. Areas covered: This paper focuses on the mechanism of action, pharmacodynamics, antihypertensive effects, adverse effects, interactions and contraindications of loop diuretics and potassium-sparing agents (including mineralocorticoid receptor antagonists (MRAs) and epithelial Na+ channel blockers). Expert opinion: Loop diuretics… Expand
Loop Diuretics in the Treatment of Hypertension
TLDR
Loop diuretics appear to have a preferable side effect profile (less hyponatremia, hypokalemia, and possibly less glucose intolerance) and their rightful place in the antihypertensive arsenal is yet to be determined. Expand
Loop Diuretics in Clinical Practice
  • S. Oh, S. Han
  • Medicine
  • Electrolyte & blood pressure : E & BP
  • 2015
TLDR
Five important aspects of loop diuretics, in particular furosemide, which must be considered when prescribing this medicine are reviewed: (1) oral versus intravenous treatment, (2) dosage, (3) continuous versus bolus infusion, (4) application in chronic kidney disease patients, and (5) side effects. Expand
Diuretics in the treatment of hypertension
TLDR
Diuretics effectively decrease blood pressure in hypertensive patients, and in adults with hypertension reduce the risk of adverse cardiovascular outcomes and common side effects of thiazides are mostly dose-related and involve electrolyte and metabolic abnormalities. Expand
Comparison of agents that affect aldosterone action.
The first aldosterone blocker, spironolactone, initially was used as a diuretic but was accompanied by a significant amount of side effects that necessitated the withdrawal of the drug in a relevantExpand
Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
TLDR
Although the diuretic hypothesis was put forward to explain the remarkable reduction in mortality with empagliflozin in EMPA-REG, the available results do not support a major contribution of this mechanism, unless the specific diUREtic effect of SGLT2 inhibitors turns out to be markedly different from those of classic diuretics. Expand
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease
TLDR
Two potassium binders, patiromer and sodium zirconium cyclosilicate, represent a new approach in the treatment of chronic hyperkalemia as they may allow the titration and maintenance of guidelines-recommended doses of RAASIs in patients with CVD who otherwise would not tolerate them due to the risk of hyperKalemia. Expand
Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
TLDR
Lixisenatide affects postprandial urinary excretion of several electrolytes and increases urinary pH compared with insulin glulisine in T2DM patients after 8 wk of treatment, most likely explained by a drug-induced rise in blood pressure or direct inhibitory effects on NHE3 in the proximal tubule. Expand
Resistant Hypertension in People With CKD: A Review.
  • K. Fay, D. Cohen
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2020
TLDR
This work discusses the evaluation of patients with resistant hypertension, the management of established resistant hypertension including medication optimization, recent clinical trials supporting lifestyle modifications, and the evidence behind the routine use of mineralocorticoid receptor antagonists. Expand
The double challenge of resistant hypertension and chronic kidney disease
TLDR
Resistant hypertension in chronic kidney disease stages 3-5 is discussed in terms of worldwide epidemiology, outcomes, causes and pathophysiology, evidence-based treatment, and a call for action. Expand
Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer
ABSTRACT Introduction: Hyperkalemia is a common electrolyte disorder, especially among patients with chronic kidney disease (CKD), diabetes mellitus, or heart failure, and is associated with aExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 107 REFERENCES
Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics
TLDR
The clinical pharmacology of thiazide diuretics is reviewed to provide an insight into the mechanisms involved in their antihypertensive and adverse effects, the determinants of drug response and the possible differences in their pharmacodynamic and pharmacokinetic properties in an attempt to improve their clinical use in the treatment of arterial hypertension. Expand
Diuretic resistance: physiology and therapeutics.
TLDR
Treatment regimens can be designed to block specific adaptive mechanisms and improve diuretic effectiveness on the basis of an understanding of the mechanisms of diUREtic adaptation and resistance. Expand
Loop Diuretics in Clinical Practice
  • S. Oh, S. Han
  • Medicine
  • Electrolyte & blood pressure : E & BP
  • 2015
TLDR
Five important aspects of loop diuretics, in particular furosemide, which must be considered when prescribing this medicine are reviewed: (1) oral versus intravenous treatment, (2) dosage, (3) continuous versus bolus infusion, (4) application in chronic kidney disease patients, and (5) side effects. Expand
Loop diuretics: from the Na-K-2Cl transporter to clinical use.
TLDR
It is proposed that altered expression or activity of the sodium-potassium-chloride transporter in the loop of Henle, in conjunction with events occurring in other segments of the nephron, possibly accounts for the altered diuretic response to these agents. Expand
Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist?
TLDR
The potential use of natriuretic doses of aldosterone antagonists in patients with HF is discussed, including the potential side effect of hyperkalemia. Expand
Comparison of loop diuretics in patients with chronic renal insufficiency.
TLDR
Assessing the pharmacokinetic and pharmacodynamic characteristics of intravenously administered furosemide and bumetanide in ten adult patients with stable, chronic renal insufficiency in a randomized, cross-over study during controlled sodium intake found differences in diuretic effectiveness. Expand
Blood pressure-lowering efficacy of loop diuretics for primary hypertension.
  • K. Lisy
  • Medicine
  • The Journal of cardiovascular nursing
  • 2014
TLDR
It is important that nurses be apprised of the latest evidence regarding the use of loop diuretics for the treatment of primary hypertension and to better provide care, advice, and support to people who may require or who already are receiving blood pressure medication. Expand
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
TLDR
It is suggested that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy. Expand
Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension
TLDR
Treatment with either amiloride or spironolactone can provide an additional reduction in blood pressure in blacks already receiving conventional antihypertensive therapy, and in a substudy, plasma endothelin-1 levels were observed to decrease after 3 weeks of treatment with spironlactone, consistent with a non–ENaC-related potential benefit of spironOLactone. Expand
Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure.
TLDR
Azosemide, compared with furosemide, reduced the risk of cardiovascular death or unplanned admission to hospital for congestive HF in patients with chronic heart failure. Expand
...
1
2
3
4
5
...